TMDX · Insider Trading
TransMedics Group, Inc. Common Stock
Every open-market purchase and sale reported by TMDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-30 | Fernando N. Araujo | See Remarks | A | +22,969 | — |
| 2026-09-14 | David Weill | Director | Buy | +1,336 | +$109.06K |
| 2026-08-17 | James R Tobin | Director | G | −18,000 | — |
| 2026-07-14 | Nicholas Corcoran | See remarks | A | +11,727 | — |
| 2026-07-14 | Gerardo Hernandez | Chief Financial Officer | A | +17,246 | — |
| 2026-07-14 | Waleed H Hassanein | President & CEO | A | +49,669 | — |
| 2026-06-17 | Thomas J. Gunderson | Director | MIXED | +9,661 | −$679.76K |
| 2026-05-22 | Merilee Raines | Director | A | +2,922 | — |
| 2026-05-22 | Edward M Basile | Director | A | +2,922 | — |
| 2026-05-22 | David Weill | Director | A | +2,922 | — |
| 2026-05-22 | James R Tobin | Director | A | +2,922 | — |
| 2026-05-22 | Stephanie Lovell | Director | A | +2,922 | — |
| 2026-05-22 | Thomas J. Gunderson | Director | A | +2,922 | — |
| 2026-05-22 | Edwin Kania | Director | A | +2,922 | — |
| 2026-05-21 | Matthew S. Forsyth | See Remarks | A | +15,409 | — |
| 2026-03-06 | Stephanie Lovell | Director | Sell | −1,193 | −$178.50K |
| 2026-03-06 | David Weill | Director | MIXED | — | −$473.59K |
| 2026-03-04 | Anil P. Ranganath | See remarks | Sell | −864 | −$120.20K |
| 2026-03-04 | Nicholas Corcoran | See remarks | MIXED | −3,950 | −$545.77K |
| 2026-03-04 | Gerardo Hernandez | Chief Financial Officer | MIXED | −375 | −$602.38K |
| 2026-02-20 | Giovanni Cecere | Chief Commercial Officer | A | +11,082 | — |
| 2025-12-05 | Gerardo Hernandez | Chief Financial Officer | Sell | −920 | −$128.45K |
| 2025-12-05 | David Weill | Director | MIXED | — | −$622.20K |
| 2025-11-26 | Anil P. Ranganath | See remarks | MIXED | — | −$154.02K |
| 2025-11-18 | Waleed H Hassanein | President & CEO | Buy | +8,775 | +$1.00M |
| 2025-10-31 | Edward M Basile | Director | MIXED | — | −$537.42K |
| 2025-08-08 | Waleed H Hassanein | President & CEO | Buy | +16,875 | +$1.98M |
| 2025-08-05 | Edward M Basile | Director | MIXED | — | −$517.09K |
| 2025-06-10 | Anil P. Ranganath | See remarks | Sell | −686 | −$95.90K |
| 2025-05-29 | Edward M Basile | Director | MIXED | — | −$628.75K |
| 2025-05-23 | Merilee Raines | Director | A | +2,134 | — |
| 2025-05-23 | Edwin M Kania Jr | Director | A | +2,134 | — |
| 2025-05-23 | Stephanie Lovell | Director | A | +2,134 | — |
| 2025-05-23 | Thomas James Gunderson | Director | A | +2,134 | — |
| 2025-05-23 | David Weill | Director | MIXED | +1,402 | −$90.68K |
| 2025-05-23 | Edward M Basile | Director | A | +2,134 | — |
| 2025-05-23 | James R Tobin | Director | A | +2,134 | — |
| 2025-05-13 | Edward M Basile | Director | MIXED | — | −$689.58K |
| 2025-03-05 | Tamer I Khayal | Chief Commercial Officer | Sell | −2,407 | −$183.97K |
| 2025-02-26 | Nicholas Corcoran | See Remarks | A | +12,676 | — |
| 2025-02-26 | Anil P. Ranganath | See remarks | A | +5,634 | — |
| 2025-02-26 | Tamer I Khayal | Chief Commercial Officer | A | +17,606 | — |
| 2025-02-26 | Waleed H Hassanein | President & CEO | A | +59,781 | — |
| 2025-02-26 | Gerardo Hernandez | Chief Financial Officer | A | +3,521 | — |
| 2025-01-10 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | −$72.31K |
| 2024-12-11 | Gerardo Hernandez | Chief Financial Officer | A | +12,463 | — |
| 2024-12-04 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | −$79.26K |
| 2024-11-13 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | −$75.20K |
| 2024-11-07 | Edward M Basile | Director | MIXED | — | −$374.18K |
| 2024-11-05 | Tamer I Khayal | Chief Commercial Officer | MIXED | — | −$75.12K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Waleed H Hassanein | President & CEO | 516,102 | $37.55M |
| Edwin Kania | Director | 309,874 | $22.54M |
| James R Tobin | Director | 162,127 | $11.80M |
| Nicholas Corcoran | See remarks | 41,558 | $3.02M |
| Tamer I Khayal | Chief Commercial Officer | 36,042 | $2.62M |
| Gerardo Hernandez | Chief Financial Officer | 31,935 | $2.32M |
| Thomas J. Gunderson | Director | 26,266 | $1.91M |
| Fernando N. Araujo | See Remarks | 22,969 | $1.67M |
| Giovanni Cecere | Chief Commercial Officer | 19,057 | $1.39M |
| David Weill | Director | 16,392 | $1.19M |
| Matthew S. Forsyth | See Remarks | 15,409 | $1.12M |
| Anil P. Ranganath | See remarks | 13,091 | $952.44K |
| Merilee Raines | Director | 6,981 | $507.90K |
| Stephanie Lovell | Director | 5,788 | $421.11K |
| Edward M Basile | Director | 5,788 | $421.11K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TMDX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.